Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 01 2021
Historique:
received: 25 02 2020
revised: 29 08 2020
accepted: 11 10 2020
pubmed: 24 10 2020
medline: 21 4 2021
entrez: 23 10 2020
Statut: ppublish

Résumé

Although electroconvulsive therapy (ECT) is a highly effective, safe, and well-tolerated antidepressant treatment for late-life depression (LLD), there is large variability in response rates across individuals. We hypothesized that these variations would be in part explained by the level of vascular risk in this population. We therefore compared response rates to ECT in patients with LLD presenting with or without vascular risk factors (VRF). 52 patients with LLD (age > 55) who received a course of ECT were separated into 2 groups according to the presence of VRF (n = 20) or not (n = 32). Framingham score (10-year risk for developing a coronary heart disease) was calculated for each patient. Our primary outcome was the number of responders to ECT in each group (defined as at least 50% decrease of the Montgomery-Åsberg Depression Rating Scale score following ECT course). Scores at the self-rated Beck Depression Inventory are also reported. Patients with VRF presented significant lower response rates to ECT (12 out of 20; 60%) than patients without VRF (30 out of 32; 94%; p = 0.004). A negative correlation was found between Framingham score and changes in depression scores pre/post ECT (r = -0.42; p = 0.0039). Our study was limited by sample size and retrospective design. Patients with LLD and VRF showed lower response rates to ECT than those without VRF. The more the VRF increased, the less the antidepressant effect of ECT was observed. Results are discussed in light of the role of apathy in clinical response to ECT.

Sections du résumé

BACKGROUND
Although electroconvulsive therapy (ECT) is a highly effective, safe, and well-tolerated antidepressant treatment for late-life depression (LLD), there is large variability in response rates across individuals. We hypothesized that these variations would be in part explained by the level of vascular risk in this population. We therefore compared response rates to ECT in patients with LLD presenting with or without vascular risk factors (VRF).
METHODS
52 patients with LLD (age > 55) who received a course of ECT were separated into 2 groups according to the presence of VRF (n = 20) or not (n = 32). Framingham score (10-year risk for developing a coronary heart disease) was calculated for each patient. Our primary outcome was the number of responders to ECT in each group (defined as at least 50% decrease of the Montgomery-Åsberg Depression Rating Scale score following ECT course). Scores at the self-rated Beck Depression Inventory are also reported.
RESULTS
Patients with VRF presented significant lower response rates to ECT (12 out of 20; 60%) than patients without VRF (30 out of 32; 94%; p = 0.004). A negative correlation was found between Framingham score and changes in depression scores pre/post ECT (r = -0.42; p = 0.0039).
LIMITATIONS
Our study was limited by sample size and retrospective design.
CONCLUSION
Patients with LLD and VRF showed lower response rates to ECT than those without VRF. The more the VRF increased, the less the antidepressant effect of ECT was observed. Results are discussed in light of the role of apathy in clinical response to ECT.

Identifiants

pubmed: 33096329
pii: S0165-0327(20)32869-X
doi: 10.1016/j.jad.2020.10.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-315

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Lucie Jurek (L)

University Lyon 1, Villeurbanne F-69000, France; Centre Hospitalier Le Vinatier, Bron, France. Electronic address: Lucie.JUREK@ch-le-vinatier.fr.

Jean-Michel Dorey (JM)

Centre Hospitalier Le Vinatier, Bron, France; Brain Dynamics and Cognition, Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR 5292, Lyon, France.

Mikaïl Nourredine (M)

University Lyon 1, Villeurbanne F-69000, France; INSERM, Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response, U1028; CNRS, UMR5292, PSYR2 Team, Lyon F-69000, France.

Filipe Galvao (F)

University Lyon 1, Villeurbanne F-69000, France; INSERM, Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response, U1028; CNRS, UMR5292, PSYR2 Team, Lyon F-69000, France; Centre Hospitalier Le Vinatier, Bron, France.

Jérome Brunelin (J)

University Lyon 1, Villeurbanne F-69000, France; INSERM, Lyon Neuroscience Research Center, Psychiatric Disorders: from Resistance to Response, U1028; CNRS, UMR5292, PSYR2 Team, Lyon F-69000, France; Centre Hospitalier Le Vinatier, Bron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH